Research Analysts’ Upgrades for January, 18th (AAPL, ABBV, ABC, BTVCY, CABGY, CCHGY, CZZ, FDX, JPM, MET)

Research Analysts’ upgrades for Thursday, January 18th:

Apple (NASDAQ:AAPL) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $197.00 target price on the stock. According to Zacks, “Apple shares have vastly outperformed the S&P 500, in the past one year. The company is benefiting from steady iPhone sales, spurt in Services segment and a resurgence in Mac and iPad sales. The company is anticipated to benefit from the strong demand of iPhone X in mature markets, which will help it to sustain momentum in the near term. Going ahead, we believe foray into fast-growing technologies like autonomous vehicle, artificial intelligence (AI) & AR/VR are long-term drivers. Moreover, Apple’s new investment plan will boost its subscription-based services business and put an end to the criticism it is facing for not creating enough jobs in the United States. Estimates have remained stable ahead of the company's Q1 earnings release. The company has positive record of earnings surprises in recent quarters.”

AbbVie (NYSE:ABBV) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $115.00 price target on the stock. According to Zacks, “AbbVie’s key drug Humira has been performing well based on strong demand trends for the drug, despite new competition. Moreover, Imbruvica has multibillion dollar potential and AbbVie is exploring the possibility of label expansion into solid tumors and autoimmune diseases. AbbVie’s shares outperformed the industry in the past one year supported by a series of positive news including promising data from several pivotal studies, regulatory approvals in the U.S., Europe, and Japan for its competitive HCV medicine Mavyret and FDA approval for the sixth indication for Imbrivica and settlement of its Humira patent disputes with Amgen. Also, several pivotal data readouts and regulatory milestones are expected in 2018. However, HCV sales continue to be hurt by intensifying competition. Estimates have remained stable ahead of the Q4 earnings release. AbbVie has a positive record of earnings surprises in the recent quarters.”

AmerisourceBergen (NYSE:ABC) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $111.00 target price on the stock. According to Zacks, “Despite trading below the broader industry over the last year, AmerisourceBergen is expected to benefit from generics growth. The company has been actively pursuing acquisitions to strengthen its core areas. The recent takeover of H.D. Smith, the largest independent wholesaler in the United States, is worth a mention in this regard. The deal is worth for $815 million. Solid performance in the Pharmaceutical Distribution Segment is also a positive. On the flip side, AmerisourceBergen faces headwinds due to the slowdown in hepatitis C revenues and conversion of branded drugs to the lower price generics. Furthermore, a temporary slowdown in PharMEDium's growth is expected to mar the company’s bottom line. Cutthroat competition in niche space also adds to the woes. “

Britvic (OTCMKTS:BTVCY) was upgraded by analysts at Deutsche Bank AG from a hold rating to a buy rating.

Carlsberg A/S (OTCMKTS:CABGY) was upgraded by analysts at Deutsche Bank AG from a hold rating to a buy rating.

Coca Cola HBC (OTCMKTS:CCHGY) was upgraded by analysts at Deutsche Bank AG from a hold rating to a buy rating.

Cosan (NYSE:CZZ) was upgraded by analysts at Zacks Investment Research from a hold rating to a strong-buy rating. The firm currently has $12.00 price target on the stock. According to Zacks, “In the last three months, Cosan's American Depository Receipts (ADR) has outperformed the industry. We believe that Cosan constantly strives to improve its production capabilities and services to capitalize on the growing sugar and ethanol demand. Its strategy of expanding its network of service stations and acquiring meaningful businesses aided growth over time. Exiting third-quarter 2017, the company had 6,138 Shell branded service stations. For the crop year April 2017-March 2018, the company anticipates volume of sugarcane crushed to be within 59-63 million. Sugar volume produced is likely to come in a range of 4.3-4.7 million tons.”

FedEx (NYSE:FDX) was upgraded by analysts at Zacks Investment Research from a hold rating to a strong-buy rating. They currently have $310.00 target price on the stock. According to Zacks, “Shares of FedEx have outperformed its industry as well as rival United Parcel Service over the past year. While FedEx has gained 45.9%, the industry it belongs to and UPS have rallied 27.1% and 17.3%, respectively, in the same time period. Ushering in further good news, FedEx experienced a highly successful holiday season driven by increased package volumes. In fact, the strong growth of e-commerce is a huge positive for the company. The new tax law is also expected to aid the company significantly. The company's efforts to reward its shareholders through dividend payments and share buybacks are also encouraging. The positive sentiment surrounding the stock may be gauged from the fact that the Zacks Consensus Estimate for fiscal 2018 earnings has increased 5.3% over the last 60 days. However, high costs are hurting the bottom line. Significant investments at the company's Ground unit are pushing up costs.”

JPMorgan Chase & Co. (NYSE:JPM) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $126.00 target price on the stock. According to Zacks, “JPMorgan's shares have outperformed the industry over the past six months. This price performance is backed by impressive earnings surprise history, with the company surpassing the Zacks Consensus Estimate in each of the trailing four quarters. The company’s fourth-quarter 2017 results benefited mainly from higher interest income and investment banking fees, partially offset by lower trading revenues and mortgage banking fess along with a surge in provisions for loan losses. The bank’s efforts to manage expenses, higher interest rates and rising loan demand will likely continue to benefit its financials. While the company faces persistent fee income growth challenge, mainly due to a slowdown in trading activities and dismal capital markets performance, lower tax rates will aid profitability in the quarters ahead.”

Metlife (NYSE:MET) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $58.00 target price on the stock. According to Zacks, “MetLife's efforts to streamline its business (for the past many years) to focus on the ones with potential for growth and fixing or exiting businesses that do not create value is impressive. Its strong international operations and disciplined capital management should drive long-term growth. Though the company has lost value in a year time, it remains an attractive investment opportunity, given its Value Score of A and undervaluation relative to the industry it belongs to. However, persistent decline in MetLife’s revenues, due to lower premiums, investment income, and fees collected from Universal Life and investment type product, and other revenues for more than two years bothers us.”

Northern Dynasty Minerals (NYSEAMERICAN:NAK) (TSE:NDM) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $2.00 price target on the stock. According to Zacks, “Northern Dynasty owns the rights to purchase 100% of the Pebble gold-copper-molybdenum porphyry deposit, where successful drilling programs have delineated an Inferred Mineral Resource. Northern Dynasty is the largest gold deposit and one of the largest copper deposits in North America. “

NuCana (NASDAQ:NCNA) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $15.00 target price on the stock. According to Zacks, “NuCana PLC is a clinical-stage biopharmaceutical company. It focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The company’s pipeline of products includes Acelarin, NUC-3373 and NUC-7738 which are in clinical stage. NuCana PLC is based in EDINBURGH, United Kingdom. “

Natural Grocers by Vitamin Cottage (NYSE:NGVC) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $9.50 target price on the stock. According to Zacks, “Natural Grocers by Vitamin Cottage is a specialty retailer of natural and organic groceries and dietary supplements. The Company provides healthy foods, vitamins, and supplements including allergy, aloe products, amino acids, antioxidants, animal products, beverages, medical, cleansing and clearance, weight loss, electrolytes, energy, cosmetics, natural, minerals, vitamins, pain relief, and supplements. It has locations primarily in Colorado, Texas, Utah, Wyoming, Oklahoma, Missouri, New Mexico, Montana, Kansas, Idaho, Nebraska and Arizona. Natural Grocers by Vitamin Cottage is based in Lakewood, Colorado. “

Nice (NASDAQ:NICE) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $103.00 price target on the stock. According to Zacks, “NICE Ltd. provides enterprise software solutions. Its operating segment consists of Customer Interactions Solutions, Financial Crime and Compliance Solutions. The Company’s solutions include integrated, multimedia recording platforms, software applications and related professional services. NICE Ltd., formerly known as NICE-Systems Ltd., is headquartered in Ra’anana, Israel. “

Ntt Data (OTCMKTS:NTDTY) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $14.00 target price on the stock. According to Zacks, “NTT DATA Corp. is engaged in the development and integration of information technology and data communication systems. Its operating segment consists of Public and Financial IT Services, Enterprise IT Services, Solutions and Technologies, Global Business and Others. Public and Financial IT Services segment provides IT services which support social infrastructure in the public administration, healthcare and financial sectors. Enterprise IT Services segment offers IT services in the fields of manufacturing, retail, logistics, communications, broadcasting and utilities. Solutions and Technologies segment renders platforms and solutions that support IT services. Global Business segment delivers IT services. Others segment supports the business activities of the head office. NTT DATA Corp. is headquartered in Tokyo, Japan. “

Receive News & Ratings for Apple Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apple Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.